The group�s principle activities include discovering and developing small-molecule kinase inhibitors for the treatment of cancer. The group�s technology includes KINOMEscan(TM) technology. The group�s products include FLT3 Kinase, AURORA Kinase and BRAF Kinase. The group operates from United States.